Hefei Lifeon Pharmaceutical Co., Ltd. (003020.SZ)
CNY 18.83
(1.4%)
CNY 18.83
(1.4%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.88 Billion CNY | -27.02% |
| 2022 | 2.57 Billion CNY | 13.46% |
| 2021 | 2.27 Billion CNY | 20.01% |
| 2020 | 1.89 Billion CNY | 14.8% |
| 2019 | 1.65 Billion CNY | 15.83% |
| 2018 | 1.42 Billion CNY | 22.12% |
| 2017 | 1.16 Billion CNY | 13.46% |
| 2016 | 1.02 Billion CNY | 0.0% |
| 2014 | 962.16 Million CNY | 9.62% |
| 2013 | 877.71 Million CNY | 19.69% |
| 2012 | 733.32 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 333.61 Million CNY | -10.02% |
| 2024 Q2 | 428.84 Million CNY | 28.54% |
| 2024 Q3 | 350.79 Million CNY | -18.2% |
| 2023 Q2 | 455.97 Million CNY | -43.83% |
| 2023 Q3 | 256.71 Million CNY | -43.7% |
| 2023 Q4 | 370.75 Million CNY | 44.42% |
| 2023 FY | 1.88 Billion CNY | -27.02% |
| 2023 Q1 | 811.81 Million CNY | 18.49% |
| 2022 Q3 | 664.96 Million CNY | 10.71% |
| 2022 FY | 2.57 Billion CNY | 13.46% |
| 2022 Q4 | 685.15 Million CNY | 3.04% |
| 2022 Q2 | 600.6 Million CNY | -4.46% |
| 2022 Q1 | 628.61 Million CNY | 3.33% |
| 2021 Q2 | 524.71 Million CNY | -4.44% |
| 2021 Q1 | 549.09 Million CNY | 5.98% |
| 2021 Q4 | 608.35 Million CNY | 2.92% |
| 2021 FY | 2.27 Billion CNY | 20.01% |
| 2021 Q3 | 591.08 Million CNY | 12.65% |
| 2020 Q3 | 484.16 Million CNY | 10.16% |
| 2020 Q1 | 452.51 Million CNY | 1.03% |
| 2020 FY | 1.89 Billion CNY | 14.8% |
| 2020 Q2 | 439.52 Million CNY | -2.87% |
| 2020 Q4 | 518.09 Million CNY | 7.01% |
| 2019 Q2 | 391.92 Million CNY | 0.0% |
| 2019 FY | 1.65 Billion CNY | 15.83% |
| 2019 Q4 | 447.89 Million CNY | 7.07% |
| 2019 Q3 | 418.29 Million CNY | 6.73% |
| 2019 Q1 | 391.92 Million CNY | 0.0% |
| 2018 FY | 1.42 Billion CNY | 22.12% |
| 2017 FY | 1.16 Billion CNY | 13.46% |
| 2016 FY | 1.02 Billion CNY | 0.0% |
| 2014 FY | 962.16 Million CNY | 9.62% |
| 2013 FY | 877.71 Million CNY | 19.69% |
| 2012 FY | 733.32 Million CNY | 0.0% |